⚠️ Cannabis Psychiatric Medication Interaction Simulator

Patient on Psychiatric Medication Considers Cannabis

A stabilized patient weighs cannabis use against their prescribed regimen.

• 3: Medication classes modeled (benzo / antipsychotic / antidepressant)
• 2: Cannabis compounds tracked (THC and CBD)
• 3: Interaction pathways (sedation, psychosis, pharmacokinetic)
• Varies: Baseline risk (depends on class + potency)

Why interactions matter

Cannabis is common among psychiatric patients; effects vary widely by drug class.

Two active compounds

THC drives psychoactive and sedative effects; CBD drives enzyme inhibition effects.

What this simulator shows

Toggle medication class and THC potency to see risk pathways shift live.

Sedative Interaction — Additive CNS Depression

Cannabis compounds with sedatives, amplifying drowsiness and impairment.

• Benzodiazepine: Highest-risk class (strong additive sedation)
• CNS depression: Mechanism (additive, not multiplicative)
• THC dose: Modifier (higher potency, more sedation)
• Falls / overdose: Clinical concern (especially with other sedatives)

Additive depression

THC and benzodiazepines both dampen CNS activity, compounding sedation risk.

Dose dependence

Higher THC potency increases sedative load layered onto medication effects.

Practical impact

Impaired coordination, drowsiness, and respiratory risk rise with co-use.

THC and Antipsychotic-Treated Psychotic Disorders

High-potency THC can worsen symptoms in antipsychotic-treated patients.

• Antipsychotic: Highest-risk class (psychotic-disorder patients)
• THC potency: Key driver (high-potency products, most concern)
• Symptom relapse: Effect (or worsening psychosis)
• Non-linear spike: Interaction shape (steep rise at high THC)

Why psychosis risk spikes

THC potency interacts sharply with antipsychotic-treated psychotic disorders.

Potency matters most here

Low-THC products carry much lower relapse risk than high-potency ones.

The combined-risk case

Antipsychotic class plus high THC together produce the sharpest risk spike.

CBD and CYP450 Enzyme Inhibition

CBD inhibits CYP450 enzymes, raising blood levels of some medications.

• CYP450: Affected pathway (hepatic metabolism enzymes)
• Antidepressant / antipsychotic: Higher-risk classes (CYP-metabolized drugs)
• Elevated blood levels: Effect (increased side-effect risk)
• CBD content: Driver (not primarily THC potency)

Enzyme inhibition basics

CBD slows CYP450 enzymes that normally clear certain medications.

Who is most affected

Antidepressants and antipsychotics metabolized via these pathways see level rises.

Clinical implication

Elevated blood levels can increase side effects without a dose change.

Risk Depends on Medication Class and Diagnosis

Class and diagnosis both matter; psychotic-disorder patients face the most concern.

• Psychosis: Most sensitive pathway (for antipsychotic-treated patients)
• Sedation: Most consistent pathway (benzodiazepine co-use)
• Pharmacokinetic: Most overlooked pathway (CBD-driven level changes)
• Context-dependent: Overall takeaway (class + diagnosis + potency)

Three distinct pathways

Sedation, psychosis, and pharmacokinetic risk behave independently by class.

Highest-stakes group

Patients with psychotic disorders face the most significant specific concern.

Takeaway for practice

Assess cannabis risk per medication class and underlying diagnosis together.

Interaction risk summary by medication class